Johnson & Johnson — 2013 Form 10-K Summary
Business context and reporting period. This annual report covers the fiscal year ended December 29, 2013; it is not a standalone fourth-quarter filing. Johnson & Johnson is a global health-care company with approximately 128,100 employees and more than 275 operating companies. Its three segments are Consumer, Pharmaceutical, and Medical Devices and Diagnostics.
Financial performance and position
- Research and development: Worldwide R&D costs were $8.2 billion in 2013, compared with $7.7 billion in 2012 and $7.5 billion in 2011.
- Revenue, earnings, margins, cash flow, debt, and liquidity: The supplied filing text incorporates the financial statements and management’s discussion from the shareholder annual report but does not include their figures. The filing text provided here does not give clear values for these measures.
- Selected reserves: Schedule II reports total valuation and qualifying account balances of $4.474 billion at year-end 2013, versus $4.182 billion at year-end 2012. These include rebate, return, promotion, doubtful-account, and cash-discount accruals.
- Fourth-quarter share purchases: The company reported 5,351,965 shares purchased during the fiscal fourth quarter at varying period-average prices of $88.12, $92.95, and $94.07. Purchases under publicly announced plans were zero; the reported purchases included stock-for-stock option exercises.
Changes, outlook, and material matters
- R&D spending rose approximately 6% from 2012 to 2013, based on the reported figures.
- REMICADE accounted for approximately 9.4% of 2013 revenue. The company disclosed that key REMICADE patents expire in certain markets during 2015–2018, and that patent validity is being challenged in litigation. Loss of exclusivity could reduce sales. The filing identifies STELARA, SIMPONI, and SIMPONI ARIA as newer immunology products with approximately 10 years of remaining patent life.
- McNeil Consumer Healthcare remained subject to an FDA consent decree governing certain manufacturing operations. Remediation commitments had been met at the Las Piedras and Lancaster facilities; Fort Washington was not operating and required further investment before certification.
- The company cited increasingly stringent product regulation, health-care pricing and utilization pressures, competition, and international political and economic uncertainty as business risks. It also noted uncertainty about the effects of U.S. health-care reform.
- The company expected no material adverse impact from an environmental-regulation matter involving a California manufacturing facility and said it had reached an agreement in principle to resolve it. Other legal proceedings are incorporated by reference and are not detailed in the supplied text.
- No specific financial guidance or quantified outlook is provided in the supplied filing text. Management stated that disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Review the incorporated 2013 annual report for full-year revenue, earnings, segment results, margins, cash flows, balance-sheet liquidity, and debt figures.
- Assess REMICADE patent litigation, market-by-market exclusivity dates, and potential sales effects.
- Check the status, costs, and timing of McNeil remediation and Fort Washington facility certification.
- Review the incorporated legal-proceedings and risk-factor disclosures for the scope and potential financial impact of contingencies.
- Confirm whether management issued forward guidance elsewhere in the incorporated annual report or subsequent disclosures.